Introduction {#Sec1}
============

The concept of clinical frailty describes a state or syndrome of reduced physical, physiologic, and cognitive reserve \[[@CR1]\]. Frail patients are characterized by a heterogeneous combination of decreased mobility, weakness, reduced muscle mass, poor nutritional status, and diminished cognitive function; all of these render frail individuals more susceptible to extrinsic stressors. Although frailty is more common in older individuals \[[@CR2]\], frailty and aging are not synonymous \[[@CR3]\], and the former has been estimated to occur in approximately 25% of those over the age of 65 and over 50% of those over the age of 85 \[[@CR4]\]. Frail individuals are more likely to require assisted living, be more susceptible to adverse events, and are more likely to die when compared to age-matched non-frail individuals \[[@CR5], [@CR6]\]. Frailty has characteristic molecular and physiologic features including increases in inflammatory markers \[[@CR7]\] and epigenetic changes characterized by increased DNA methylation \[[@CR8]\].

A number of validated tools to screen for, identify, and quantify frailty have been described \[[@CR3], [@CR9]--[@CR14]\]. Frailty is increasingly recognized as a risk factor for poor outcomes across many disease states and healthcare interventions \[[@CR15]--[@CR17]\]. Similarly, there is emerging evidence that frailty status has important implications for individuals developing critical illness \[[@CR18]\].

The increased prevalence of frailty with ageing and growing utilization of critical care services by older individuals \[[@CR19]\] imply there is likely to be an increased number of frail patients being admitted to intensive care units (ICUs). Considering the diminished resilience and greater vulnerability of frail patients, they may be more likely to require and have longer durations of the life-sustaining ICU therapies but their effectiveness in this population is unclear. Studies to date of critically ill frail patients have utilized a variety of designs, include variable populations and report on a range of outcomes. There is a need to synthesize the evidence in its entirety to understand if it can inform prognostication or decision-making and to identify knowledge gaps to inform future research including the potential for targeted interventions. Therefore, we conducted a systematic review and meta-analysis of the impact of frailty on outcomes for critically ill frail patients admitted to the ICU. We hypothesized that frailty would be associated with higher hospital and long-term mortality, increased utilization of healthcare resources, and prolonged institutionalization. An abstract of this study has been accepted for presentation at the 2017 European Society of Intensive Care Medicine Conference \[[@CR20]\].

Methods {#Sec2}
=======

This systemic review was conducted and reported according to Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Guidelines (see Appendix for Moose checklist) \[[@CR21], [@CR22]\]. The protocol was registered on PROSPERO (ID: CRD42016053910) in December 2016 after the initial literature search but before the literature search was subsequently updated in January and April of 2017. Eligible studies included observational studies or randomized controlled trials (RCT) that reported on frailty in ICU settings. Studies were included if they included adults (age ≥18 years) admitted to the ICU, reported on patient or health services outcomes, and used a validated tool to identify frailty. In order to best evaluate the impact of frailty, only studies comparing frail and non-frail populations were included. Narrative reviews, editorials, case reports, case-series, animal studies, and duplicate publications were excluded. Published abstracts were eligible for inclusion and there were no language restrictions.

Search strategy {#Sec3}
---------------

We electronically searched MEDLINE, EMBASE, CINAHL, and PubMed databases initially in June 2016 which was then updated in December 2016 and April 2017. Our search strategy cross-referenced frailty and ICUs using appropriate medical subject headings (MeSH) and keywords (Appendix---Search strategies). The references from selected articles and reviews were manually searched for additional studies. We also searched trial registries and conference abstracts for completed but unpublished studies. The searches were developed and conducted in consultation with a research librarian. A protocol for this review has not been published separately.

Study selection {#Sec4}
---------------

Two authors (AV and BW) independently evaluated the retrieved titles and abstracts of all articles to identify potentially relevant studies. Full-text review was conducted when either reviewer deemed that the abstract warranted further investigation on the basis of our a priori eligibility criteria. Any disagreement was resolved by discussion and consensus.

Data extraction {#Sec5}
---------------

Data were independently extracted by AV and BW and subsequently verified by JM. Data extracted included the following: author, study design, frailty identification method, number of frail and non-frail patients, and outcomes of interest. Outcomes were chosen a priori and based on two domains; patient-centered outcomes and health services utilization. We collected both unadjusted data and adjusted data. The primary outcomes were in-hospital and long-term mortality (≥6 months following ICU admission). Although hospital mortality was initially chosen as the primary outcome, long-term mortality was later added to the primary outcome with increased availability of data for this outcome. Secondary patient-centered outcomes were ICU mortality and health-related quality-of-life (HRQL). Secondary health service utilization outcomes were ICU and hospital length of stay, receipt of vasoactive agents, receipt and duration of mechanical ventilation (MV), and discharge disposition.

Assessment of quality {#Sec6}
---------------------

The Newcastle-Ottawa Scale (NOS) was used to assess for study quality \[[@CR23]\]. The NOS has three domains based on selection of the cohort, comparability of the groups, and quality of the outcomes. The NOS is a nine-point scale with a maximum of four points allocated to selection, two points for comparability, and three points for outcome. The reference for cohort selection was a general medical-surgical adult ICU population and the outcome reference was in-hospital mortality. Studies scoring 7 or more were considered high quality; 4--6, moderate quality; and 4 or less, low quality.

Data analysis {#Sec7}
-------------

A meta-analysis was performed, where possible, using Review Manager 5.3 software (Cochrane Collaboration). We primarily pooled unadjusted data, although where possible we pooled adjusted data. For the purposes of data aggregation where more than one frailty scale was reported, we used the scale most commonly reported across all the included studies. We calculated pooled risk ratio (RR) and 95% confidence intervals (95% CI) using a random effects model for dichotomous outcomes and weighted mean difference with 95% CIs for continuous data. Where data were reported as medians it was converted to means and standard deviation \[[@CR24]\]. Additional unpublished data were sought from authors. A priori planned subgroup analyses were conducted on the basis of the method of frailty identification, the severity of frailty, age of included subjects, and study quality. We hypothesized that the method of frailty identification would significantly change the effect estimate on outcomes, that increasing severity of frailty would be associated with higher mortality, that older frail patients would have higher mortality, and that there would be a decrease in the strength of association between frailty and outcomes in high quality studies.

Statistical heterogeneity was determined using the Mantel--Haenszel (M--H) Chi-squared test and the interclass correlation (*I* ^2^) statistic \[[@CR25]\]. Significant heterogeneity was defined as *I* ^2^ \> 50% or as *p* \< 0.10 with the Mantel--Haenszel Chi-squared test. Funnel plots were used to visually inspect for publication bias. We considered an unadjusted, two-sided *p* \< 0.05 to be statistically significant. To assess the probability that the results obtained were robust, we conducted trial sequential analysis (TSA) on long-term mortality with a two-sided *α* = 5%, a power of 90%, and the assumption that the absence of frailty would be associated with at least a 20% relative risk reduction in long-term all-cause mortality. The TSA was conducted with version 0.9.5.5 Beta ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)).

Results {#Sec8}
=======

Study selection {#Sec9}
---------------

The initial search identified 1413 articles and abstracts (Appendix Fig. 1). After screening the titles and abstracts, 406 duplicates and 204 unrelated papers were excluded. A further 776 titles were excluded on the basis of publication type. Twenty-nine full-text articles were assessed; 17 studies did not meet inclusion criteria, leaving a total of 12 publications from 10 separate studies fulfilling eligibility since two studies reported new data in two separate publications each \[[@CR26]--[@CR37]\].

Summary of studies {#Sec10}
------------------

The characteristics of the included studies are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. All were prospective observational cohort studies where frailty was measured on ICU admission; the majority were conducted in medical-surgical ICUs. Frailty was assessed using the clinical frailty scale (CFS) \[[@CR3]\] in seven studies, a frailty index (FI) \[[@CR38]\] in four, and the frailty physical phenotype (FP) \[[@CR39]\] in two (Table [3](#Tab3){ref-type="table"}). Of 3030 patients enrolled in the ten studies, 927 patients were classified as frail and 2103 as non-frail patients. The pooled prevalence of frailty in the ICU populations studied was 30% (95% CI 29--32%) (Fig. [1](#Fig1){ref-type="fig"}).Table 1Characteristics of included studiesReferenceStudy designInclusion criteriaExclusion criteriaCohort sizeAge\
Illness severity (SD or IQR)Frailty scale(s) used and how determinedModification of scale(s) (Y/N) training for assessors (Y/N)Frailty definitionNumber frail/non-frailOutcomes assessedOutcomes reported by frailty severity (Y/N)*nn* (%)Bagshaw \[[@CR26]\]Prospective observational multicenter cohort study in 6 Canadian ICUsAge \>50 years\
Consent obtainedICU stay \<24 h\
Previous study enrollment42167 (10) years\
APACHE II: 20 (7)CFS (9 point)\
Interview with pt., surrogate, or caregiverNo\
YesCFS \> 4Frail: 138 (33)\
Non-frail 283 (67)Mortality, morbidity, health service utilization, AEs, QoL, discharge dispositionYesBrummel \[[@CR32]\]Prospective observational multicenter study in 5 ICUs in the USAAge ≥18\
Treated for respiratory failure or shockOrgan dysfunction for \>72 h\
Recent ICU admission\
Severe cognitive impairment\
Inability to speak in English\
Substance abuse,\
Homeless or too far from study site104062 (53--72) years\
APACHE II: 24 (18--30)CFS (7 point)\
Interview with pt. or proxy and review of medical recordNo\
YesCFS \> 4Frail: 307 (30)\
Non-frail 733 (70)Mortality, morbidity, health service utilization, AEs, QoL, discharge dispositionYesFisher \[[@CR31]\]Prospective observational feasibility study in an Australian ICUAll patients admitted to ICU over 3 monthsAnticipated death within 24 h\
Admission for palliation or for organ donation20560 (17.4) years\
APACHE III: 24 (26)CFS (9 point)\
Interview with next of kin or from chart reviewNo\
YesCFS \> 4Frail: 28 (14)\
Non-frail: 177 (86)Mortality, health service utilization, discharge to rehabYesHeyland \[[@CR35], [@CR36]\]Prospective observational multicenter study in 24 Canadian ICUsAge ≥80 years\
ICU stay \>24 hNon-Canadian residents\
Lack of family members61084 (3) years\
APACHE II: 22 (7)CFS (7 point)\
FI (43 item) from CGA\
Interview with surrogate or caregiverYes\
YesCFS \> 4\
FI \> 0.2Frail:\
  CFS: 193\
  FI: 360\
Non-frail:\
  CFS: 416 FI: 250Mortality, morbidity, health service utilization, QoL, discharge dispositionYesHope \[[@CR30], [@CR37]\]Prospective observational single-center study in the USACritically ill adult patientsNR8457.4 (18.6) years\
APACHE IV: 60.1 (24.7)CFS\
FAT ICU\
Interview with surrogateYes\
NRCFS N/R\
FAT-ICU \> 3Frail:\
  CFS: 29 (35)\
  FAT-ICU: 23 (27)\
Non-frail:\
  CFS: 55 (65)\
  FAT-ICU: 61 (73)Mortality, health service utilizationNoHope \[[@CR33]\]Prospective observational cohort study in two centers in the USAAge ≥18 years\
ICU admission within 30 days of ER admit\
ICU admit for non-elective procedureICU stay expected \<24 h\
Did not speak English or Spanish\
No surrogates available9557.1 (17.5) years\
APACHE IV: 60.2 (22)CFS (9 point)\
Interview with patient or surrogateNo\
YesCFS \> 4Frail: CFS: 34 (36)\
Non-frail: 61 (64)Mortality, morbidity, health service utilizationYesKizilarslanoglu \[[@CR27]\]Prospective observational single-center study of patients in a medical ICU in TurkeyAge \>60 yearsInability to evaluate functional, physical, and mental status prior to ICU12271 (range 60--101) years\
N/RFI (55 item) from CGA\
Interview with next of kinNo\
N/RFI \> 0.4Frail: 26 (21)\
Non-frail: 96 (79)Mortality, morbidity, health service utilizationYesLe Maguet \[[@CR28]\]Prospective observational multicenter study in 4 French ICUsAge \>65 years\
ICU stay \>24 hNo surrogates and patient could not be interviewed19675 (6) years\
SAPS II: 48 (17)FP\
CFS (9 point)\
Interview with patient or relativeNo\
N/RFP \> 2\
CFS \> 4Frail:\
  FP: 80 (41)\
  CFS: 46 (24)\
Non-frail:\
  FP: 116 (59)\
  CFS: 150 (76)Mortality, morbidity, health service utilizationYesMueller \[[@CR29]\]Prospective observational study in two surgical ICUs at 1 center in the USAAge \>18 years\
ICU stay \>24 hPatients from nursing homes\
Pre-existing paralysis10261.9 (15.8) years\
APACHE II: 10 (7--15)FI (50 item)\
Interview with patient or proxyNo\
N/RFI \> 0.25Frail: 39 (38)\
Non-frail: 63 (62)Mortality, morbidity, health service utilizationNoZeng \[[@CR34]\]Prospective observational study in a geriatric ICU in ChinaAge \>65 yearsNone reported15582.7 (7.1) years\
APACHE II: 14.6 (5.8)FI (52 items)\
ICU admission recordsYes\
N/RFI \> 0.22Frail: 93 (60)\
Non-frail: 62 (40)MortalityYes*ICU* intensive care unit, *SD* standard deviation*, IQR* interquartile range, *QoL* quality of life, *CFS* clinical frailty scale, *FI* frailty index, *pt.* patient, *LOS* length of stay, *FAT*-*ICU* frailty assessment tool for intensive care unit (FAT-ICU), *APACHE* acute and chronic health evaluation, *SAPS* simplified acute physiology score, *FP* frailty phenotype Table 2Frailty outcomes in included studiesReferenceHospital mortalityICU mortalityHospital LOSICU LOS6-month mortality12-month mortalityHospital re-admissionPatients having adverse eventsDischarge disposition12-month quality of life^a^*n* (%)*n* (%)Mean (SD) or median (IQR) daysMean (IQR) or median (IQR) days)*n* (%)*n* (%)(%)*n* (%)*n* (%)Mean (SD)Bagshaw \[[@CR26]\]Frail: 44 (31.9)\
Non-frail: 45 (15.9)Frail: 16 (11.6)\
Non-frail: 27 (9.5)Frail: 30 (10--64)\
Non-frail: 18 (10--40)Frail: 7 (4--13)\
Non-frail: 6 (3--10)N/RFrail: 45 (32.6)\
Non-frail: 60 (21.2)Frail: 51/91 (56)\
Non-frail: 92/235 (35)Frail: 54 (39.1)\
Non-frail: 83 (29.3)Home independently:\
  Frail: 20 (22.0)\
  Non-frail: 104 (44.3)\
Home with help:\
  Frail: 33 (36.3)\
  Non-frail: 58 (24.7)\
Institution:\
  Frail: 38 (41.8)\
  Non-frail: 73 (31.1)EQ VAS (*n* = 67)\
Frail: 54 (23)\
Non-frail: 68 (18)Brummel \[[@CR32]\]Frail: 84 (27%)\
Non-frail: 130 (18%)Frail: 65 (21%)\
Non-frail: 113 (15%)Frail: 10.0 (6.0--17.1)\
Non-frail: 9.9 (5.9--17.2)Frail: 5.4 (2.9--11.1)\
Non-frail: 5.0 (2.6--11.0)N/RFrail: 165 (53.7)\
Non-frail: 253 (34.5)N/RN/RN/RSF-36 (*n* = 450)\
Frail:\
  Mental: 54 (40--62)\
  Physical: 26 (20--36)\
Non-frail:\
  Mental: 55 (43--60)\
  Physical: 33 (26--44)Fisher \[[@CR31]\]Frail: 4 (14.3)\
Non-frail: 29 (16.3)Frail: 1 (3.6)\
Non-frail: 6 (3.4)N/RN/RN/RN/RN/RN/RRehabilitation:\
  Frail: 6 (21)\
  Non-frail: 26 (14.7)N/RHeyland^b^ \[[@CR35], [@CR36]\]Frail: 63 (33)\
Non-frail: 95 (23)Frail: 29 (15)\
Non-frail: 56 (14)Frail: 21 (11--48)\
Non-frail: 21 (12--37)Frail: 6 (4--10)\
Non-frail: 7 (4--12)N/RFrail: 106 (55)\
Non-frail: 146 (35)N/RN/RHome:\
  Frail: 43 (22.2)\
  Non-frail: 153 (36.7)\
Acute care institution:   Frail: 34 (17.6)\
  Non-frail: 109 (26.2)\
Long-term care:   Frail: 43 (22.2)\
  Non-frail: 38 (9.1)NRHope^b^ \[[@CR30], [@CR37]\]Frail: 11 (32.4)\
Non-frail: 17 (30.9)N/RN/RN/RN/RN/RN/RN/RN/RN/RHope^b^ \[[@CR33]\]Frail: 11 (32.4)\
Non-frail: 6 (9.8)N/RFrail: 29.1 (19.9))\
Non-frail: 21.3 (24.2)N/RFrail: 15 (44.1)\
Non-frail: 16 (26.2)N/RN/RN/RN/RN/RKizilarslanoglu^b^ \[[@CR27]\]Frail: 19 (73.1)\
Non-frail: 50 (52.1)Frail: 18 (69.2)\
Non-frail: 45 (46.9)N/RN/RFrail: 22 (84.6)\
Non-frail: 59 (61.4)N/RN/RN/RN/RN/RLe Maguet^b^ \[[@CR28]\]FP frail: 29 (36)\
FP non-frail: 36 (31)\
CFS frail: 23 (50)\
CFS non-frail: 42 (28)FP frail: 22 (28)\
FP non-frail: 19 (24)\
CFS frail: 17 (37)\
CFS non-frail: 24 (16)FP frail: 21 (13--42)\
FP non-frail: 24 (13--50)\
CFS frail: 22 (13--42)\
CFS non-frail: 24 (13--49)FP frail: 7 (4--14)\
FP non-frail: 10 (5--18)\
CFS frail: 8 (4--14)\
CFS non-frail: 9 (5--18)FP frail: 23 (29)\
FP non-frail: 29 (25)\
CFS frail: 27 (59)\
CFS non-frail: 45 (30)N/RNRNRHome:\
  FP frail: 35 (44)\
  FP non-frail: 66 (57)\
  CFS frail: 13 (28)\
  CFS non-frail: 88 (59)\
Institution:\
  FP frail: 12 (15)\
  FP non-frail: 11 (9)\
  CFS frail: 15 (33)\
  CFS non-frail: 6 (4)N/RMueller \[[@CR29]\]Frail: 5 (13)\
Non-frail: 0 (0)N/RFrail: 14.6 (11.7)\
Non-frail: 8.4 (5.0)Frail: 6.1 (6.2)\
Non-frail: 3.6 (2.3)N/RN/RN/RN/RHome:\
  Frail: 12 (31%),\
  Non-frail: 45 (71)\
Rehabilitation facility:\
  Frail: 13 (33%),\
  Non-frail: 14 (22)\
Nursing home:\
  Frail: 9 (23)\
  Non-frail: 4 (6)N/RZeng \[[@CR34]\]N/RN/RN/RN/RN/RN/RN/RN/RN/RN/R*ICU* intensive care unit, *QoL* quality of life, *CFS* clinical frailty scale, *pt.* patient, *LOS* length of stay, *N/R* not reported or not available, *EQ VAS* EuroQol visual analogue scale, *SF*-*36* short form 36 item, mental and physical components^a^Quality of life as reported in the study^b^Outcomes reported are based on the CFS Table 3Summary of frailty instruments used in the included studiesInstrumentDescriptionCharacteristics of toolDefinition of frailtyValidation^a^CommentsClinical frailty scale (CFS) \[[@CR3]\]Nine-point scale based on subjective assessment of functional statusScale ranges from very fit (CFS = 1) to very severely frail (CFS = 8) and terminally ill (CFS = 9). Examples: very fit people are robust, active, energetic, and motivated while very severely frail is defined as someone who is completely dependent, approaching end of lifeUsually CFS ≥ 4YesScale is simple and easy to use. It can be used by a variety of healthcare professionalsFrailty index (FI) \[[@CR37]\]Deficit model of frailty assessment where the degree of frailty is calculated by dividing the total deficits by the total number items assessedUsually 30--70 items are assessed. Any item can be included in the index as long as it meets the following criteria:\
Item deficits increase with age\
Item is associated with health\
Item does not saturate with increasing age\
Items must cover a range of systemsUsually\
FI \> 0.2YesOften based on a comprehensive geriatric assessment including cognition, functional status, and co-morbid illnesses. Large number of items included can be challenging for its routine use, although it can be imbedded in clinical systems to make use of existing dataFrailty phenotype (FP) \[[@CR9]\]Frailty tool based on the presence of physical phenotypic featuresCalculated by the number of phenotypic features present:\
Weakness\
Slowness\
Physical activity\
Weight loss\
Self-reported exhaustionUsually\
FP \> 2YesFocused on objective and self-reported criteria for physical function. No assessment of cognition^a^Scale validated to correlate with risk of adverse events, adverse outcomes from medical interventions, need for hospitalization, need for institutionalization and death in non-ICU populations Fig. 1Prevalence of frailty in the included studies using all measures of frailty

Study quality {#Sec11}
-------------

There were no randomized controlled studies and the overall quality of the studies was moderate with mean (SD) NOS score of 6.5 (1.3) and a range of 5--8 (Table [4](#Tab4){ref-type="table"}). There were five high quality studies with a score of 7 or above \[[@CR26], [@CR27], [@CR32], [@CR33], [@CR35]\].Table 4Assessment of study quality using the Newcastle-Ottawa quality assessment scale for cohort studiesSelectionComparabilityOutcomeCohort is representative of a general adult ICU population^a^Determination of frailty was applied uniformly^b^Ascertainment of exposure\
(Frail and non-frail cohorts were selected from the same cohort)Demonstration\
that the outcome of interest was not present at study initiation^c^Comparability of cohorts on the basis of the design or analysis^d^Outcome assessmentFollow-up long enough for outcome to occurAdequacy of follow-up of cohortsStudy controls for ageCo-founders controlledBagshaw \[[@CR26]\]----✩✩✩✩✩✩Fisher \[[@CR31]\]--✩✩✩----✩✩Brummel \[[@CR32]\]--✩✩✩✩✩✩Heyland \[[@CR35], [@CR36]\]--✩✩✩✩✩✩✩Hope \[[@CR30], [@CR37]\]----✩----✩✩Hope \[[@CR33]\]--✩✩✩✩✩Kizilarslanoglu \[[@CR27]\]--✩✩✩✩✩✩✩--Le Maguet \[[@CR28]\]----✩✩----✩✩Mueller \[[@CR29]\]\
2015--✩✩----✩✩--Zeng \[[@CR34]\]--✩✩✩--✩--^a^Studies did not receive a point if there were age restrictions, the study only considered a specialized ICU population, consecutive patients were not enrolled, or a large number of patients were missed^b^Studies did not receive a point if the determination of frailty for individual patients was based on different interview sources such as the patient or a proxy^c^All studies received a point since the primary outcome was hospital mortality^d^Studies received points if baseline factors such as age, co-morbidities, and severity of illness were accounted for in statistical models with hospital mortality as the dependent variable

Mortality {#Sec12}
---------

All ten studies reported on mortality. Data could be abstracted for hospital mortality in nine studies, ICU mortality in six studies, and long-term mortality in six studies. Pooled unadjusted data using any frailty measure revealed an increased risk for frail patients compared to non-frail patients for hospital mortality (RR 1.71; 95% CI 1.43, 2.05; *p* \< 0.00001; *I* ^2^ = 32%) and long-term mortality (RR 1.53; 95% CI 1.40, 1.68; *p* \< 0.00001; *I* ^2^ = 0%) (Fig. [2](#Fig2){ref-type="fig"}). Pooled ICU mortality data revealed significantly increased risk of mortality for those identified as frail (RR 1.51; 95% CI 1.31, 1.75; *p* \< 0.00001; *I* ^2^ = 8%) (Appendix Fig. 2). TSA for long-term mortality found that the required information size was 1514 and the *Z* line crossed both conventional boundaries and information size indicating that the association of frailty and long-term mortality was robust (Appendix Fig. 3).Fig. 2Forest plot of the risk ratio for hospital and long-term mortality (\>6 months) in frail and non-frail patients using all measures of frailty

ICU and hospital length of stay (LOS) {#Sec13}
-------------------------------------

Six studies reported hospital LOS \[[@CR26], [@CR28], [@CR29], [@CR32], [@CR33], [@CR35]\] and five studies ICU LOS \[[@CR26], [@CR28], [@CR29], [@CR32], [@CR35]\]. Pooled hospital and ICU LOS demonstrated non-statistically significant longer stays for frail patients with the mean differences being 3.39 days (95% CI −0.33, 7.10; *p* = 0.07; *I* ^2^ = 77%) and 0.33 days (95% CI −0.78, 1.44; *p* = 0.56; *I* ^2^ = 73%) (Appendix Fig. 4) respectively.

Mechanical ventilation and vasopressors {#Sec14}
---------------------------------------

Five of the 10 studies, which included 703 frail and 1591 non-frail patients, reported on receipt of MV \[[@CR26], [@CR27], [@CR29], [@CR32], [@CR35]\]. There was no difference between groups in the use of MV (80% vs 82% for frail vs. non-frail patients respectively: RR 1.01; 95% CI 0.93, 1.10; *p* = 0.81; *I* ^2^ = 67%). Only one study compared MV duration between groups and found no difference \[[@CR28]\]. In addition, five of the 10 studies, which included 442 frail and 1008 non-frail patients, compared the use of vasoactive therapy between these groups \[[@CR26]--[@CR29], [@CR35]\]. There was no difference in the use of vasoactive therapy (58% vs 56% for frail vs. non-frail patients respectively: RR 1.05; 95% CI 0.88, 1.26; *p* = 0.57; *I* ^2^ = 61%).

Discharge to home versus hospital or assisted living {#Sec15}
----------------------------------------------------

Five of the 10 studies reported on discharge disposition \[[@CR26], [@CR28], [@CR29], [@CR31], [@CR35]\]. The discharge destinations included home, rehabilitation facility, nursing home, or another acute care institution. As a result of the variety of post-discharge settings, we were only able to aggregate data for home which was reported in four studies \[[@CR26], [@CR28], [@CR29], [@CR35]\]. In these studies, reporting on 416 frail and 912 non-frail patients, frail patients were less likely to be discharged home (RR 0.59; 95% CI 0.49, 0.71; *p* \< 0.00001; *I* ^2^ = 12%) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot of the risk ratio for discharge home in frail and non-frail patients

Quality of life {#Sec16}
---------------

Only two studies reported on HRQL \[[@CR26], [@CR32], [@CR40]\]. Both studies reported reduced quality of life at 1 year related to poor physical function in those who were identified as being frail on ICU admission (Table [2](#Tab2){ref-type="table"}). Bagshaw et al. also found worsened quality life related to mental health.

Subgroup analyses {#Sec17}
-----------------

### Frailty measure {#Sec18}

We conducted subgroup analysis for the association of frailty, as measured with the CFS, FI, and FP, with hospital and long-term mortality (Fig. [4](#Fig4){ref-type="fig"}, Appendix Fig. 5). In the seven studies using the CFS data could be pooled including 775 frail and 1875 non-frail patients \[[@CR26], [@CR28], [@CR31]--[@CR33], [@CR35], [@CR37]\] and the RR for hospital mortality was 1.54; 95% CI 1.33, 1.77; *p* \< 0.00001; *I* ^2^ = 0%. For the two studies pooled on the basis of an FI, the RR for hospital mortality was 3.71; 95% CI 0.22, 63.42; *p* = 0.36; *I* ^2^ = 76% \[[@CR27], [@CR29]\] and for two studies reporting on hospital mortality using the FP \[[@CR28], [@CR33]\] RR was 1.24; 95% CI 0.85, 1.81; *p* = 0.32; *I* ^2^ = 0%. On testing for interaction, there was not a statistically significant difference between the measures of frailty for the risk of hospital and long-term mortality (*p* = 0.49 and *p* = 0.26, respectively).Fig. 4Forest plot of the risk ratio for hospital mortality in frail and non-frail patients categorized according to the measure of frailty used

### Severity of frailty {#Sec19}

Of the ten studies, eight reported on the incremental risk of adverse outcomes, mainly mortality, with increasing frailty score; seven demonstrated increased risk with increased frailty severity while only one did not demonstrate an association. Differences in methods of reporting precluded pooling of data. Bagshaw et al. reported that increases in frailty severity as measured by the CFS incrementally increased risk of death adjusted for age, co-morbidities, and severity of illness at 1 year relative to those not frail \[[@CR26]\]. Similarly, Brummel et al. reported a stepwise increase in 12-month mortality with each CFS point increase; a CFS of 1 was associated with approximately 90% 1-year survival rate, a CFS of 5 had 50% survival, and those with a CFS of 6/7 had a 35% survival rate \[[@CR32]\]. Heyland et al. found that increasing FI was associated with decreased chance of being discharged home and that at 12 months, in multivariate models for every 0.2 increase in FI, the odds ratio of recovery to baseline physical function was 0.32 (0.19, 0.56; *p* \< 0.0001) and survival was 0.56 (0.37, 0.85; *p* = 0.007) \[[@CR35]\]. Kizilarslanoglu et al. categorized patients as robust (FI \< 0.25), pre-frail (FI 0.25--0.40), and frail (FI \> 0.40); 6-month mortality increased as the FI increased, 55.9%, 70.3%, and 84.6% respectively \[[@CR27]\]. Le Maguet el al. demonstrated that increasing CFS scores and increasing FP frailty characteristics were associated with increased risk of mortality at 6 months \[[@CR28]\]. Mueller et al. found that increasing FI correlated with reduced muscle mass as measured by ultrasound \[[@CR29]\]. Similarly Zeng et al. found that the degree of frailty as measured by FI correlated with increased risk of mortality at both 30 days and 300 days \[[@CR34]\]. Only one single-center study did not find a significant correlation between increasing CFS and mortality \[[@CR31]\].

### Impact of age {#Sec20}

Six studies adjusted for age in the association between frailty and outcome \[[@CR26], [@CR27], [@CR32]--[@CR35]\] and in all of these studies, frailty was independently associated with adverse outcomes. Five of the studies included older adults of a minimum age as part of their inclusion criteria; one used the age of 50 \[[@CR26]\], one used 60 \[[@CR27]\], two used the age of 65 \[[@CR28], [@CR34]\], and one used the age of 80 \[[@CR35]\]. The incidence of frailty in studies enrolling only older adults was 33.1% (95% CI 23.4, 43.5%) compared to 30% in all the included studies.

### Study quality {#Sec21}

There were five high quality studies \[[@CR26], [@CR27], [@CR32], [@CR33], [@CR35]\] all reporting on hospital and long-term mortality. In these studies, frailty continued to be associated with increased risk of hospital and long-term mortality (RR 1.63; 95% CI 1.38, 1.91; *p* \< 0.0001; *I* ^2^ = 15% and RR 1.51; 95% CI 1.37, 1.66; *p* \< 0.0001, *I* ^2^ = 0%, respectively) (Appendix Figs. 6 and 7). On testing for interaction, we found that the increased risk for both hospital and long-term mortality was similar in both the high and low quality studies, (*p* = 0.54 and *p* = 0.15, respectively).

Adjusted outcomes {#Sec22}
-----------------

Nine studies reported outcomes adjusted for co-variates including age, illness severity, and co-morbidities, although there was a large degree of variability in the adjusted outcomes reported and the co-variates included in the adjustment models. All of the adjusted data reported in the studies is summarized in Table [5](#Tab5){ref-type="table"}. We were only able to aggregate adjusted data for three studies reporting on long-term mortality \[[@CR26], [@CR28], [@CR32]\]. In this pooled adjusted data (Appendix Fig. 8), frailty was associated with increased risk of long-term mortality with a hazard ratio of 1.75 (95% CI 1.36, 2.24; *p* \< 0.0001; *I* ^2^ = 43%).Table 5Adjusted outcomes reported in the included studiesStudyAdjusted outcome(s) reportedMethod and co-variates adjustedAssociation of frailty with adjusted outcome^a^Incremental value of frailty for predicting outcomeBagshaw \[[@CR26]\]1-year mortalityMultiple models adjusted for combinations of age, sex, Elixhauser score, APACHE II, SOFA, hospital typeMortality:\
  1 year: HR 1.82, 1.28--2.60\
(In all models, frailty was associated with a dose dependent increase in 1-year mortality)Yes: frailty as defined by the CFS was associated with increased mortality at 1 yearBrummel \[[@CR32]\]Hospital mortality\
3-month mortality\
1-year mortality\
3- and 12-month IADL disability\
3- and 12-month BADL disability\
RBANS score\
SF-36 physical component\
SF-36 mental componentAdjustment for age, sex, education, comorbidity, ADL, baseline IQCODE, SOFA, CAM-ICU, RASS of −4 or −5, days of severe sepsis, days of MV, daily sedative and opiate dosesMortality:\
  Hospital: HR 1.1, 0.9--1.5, *p* = 0.56\
  3 month: HR 1.4, 1.1--1.8, *p* = 0.01\
  1 year: HR 1.5, 1.2--1.8, *p* \< 0.001\
IADL disability:\
  3 month: HR 1.2, 1.0--1.4, *p* = 0.04\
  12 month: HR 1.3, 1.1--1.6, *p* = 0.002\
BADL disability:\
  3 month: HR 1.1, 0.9--1.3, *p* = 0.23\
  12 month: HR 1.1, 0.9--1.4, *p* = 0.10\
RBANS Score:\
  3 month: −0.6, −1.7 to 0.4, *p* = 0.42\
  12 month: −0.2, −1.6 to 1.2, *p* = 0.12\
SF-36:\
  3 month physical: −2.1, −3.0 to −1.1, \< 0.001\
  1 year physical: −1.9, −2.9 to −0.8, \< 0.001\
  3 month mental: 0.5, −0.9 to 2.0, *p* = 0.08\
  1 year mental: −0.5, −2.0--1.0, *p* = 0.16Yes: frailty as defined by the CFS was associated with increased mortality, increased IADL disability, and reduced SF-36 physical at 3 months and 1 year\
No: frailty as defined by the CFS was not associated with hospital mortality, BADL disability, RBANS, and SF-36 mental at 3 months and 1 yearFisher \[[@CR31]\]Hospital length of stay\
ICU length of stayAdjustment for severity of illness severity and requirement for palliative careHospital LOS (days): 0.1 ± 0.05, *p* = 0.04)\
ICU LOS: No significant differenceNo: frailty as defined by the CFS was not associated with clinically significant increases in hospital or ICU LOSHope \[[@CR30], [@CR37]\]Adjusted outcomes not reportedHeyland \[[@CR35], [@CR36]\]Physical recovery\
1-year survivalMultivariate model: adjustment for age, sex, APACHE II, admission diagnosis, ICU diagnosis, baseline physical function, co-morbidity, IQCODE, family preferencesPhysical recovery:\
  1-year prediction of physical recovery per 0.2 increase of FI: OR 0.32, 0.19--0.56, *p* \< 0.0001\
Survival:\
  Per 0.2 increase of FI: OR 0.53, 0.36--0.78, *p* = 0.002Yes: increasing frailty as measured by the FI was associated with reduced physical recovery and reduced survival at 1 yearHope \[[@CR33]\]Increased disability at hospital discharge\
Increased disability or death at 6 monthsMultivariate model: adjustment for age, receipt of MVIncreased disability at hospital discharge:\
  CFS: OR 1.8, 0.6--5.5\
  FP: OR 2.3, 0.9, 6.2\
Increased disability or death at 6 months:\
  CFS: OR 3.8, 1.2, 11.7\
  FP: OR 4.7, 1.6, 14.3Yes: frailty as measured by a CFS \>4 or a FP \>2 was associated with increased disability at hospital discharge or the composite of death/disability at 1 yearKizilarslanoglu \[[@CR27]\]ICU mortality\
Hospital mortalityMultivariate model: adjustment for age, ICU LOS, SOFA, APACHE IIMortality:\
  ICU: HR 39.0, 1.2--1232.5, *p* = 0.038\
  Hospital: HR 36.1, 0.9--1449.2, *p* = 0.057Yes: frailty as measured by FI was associated with increased ICU mortality\
No: frailty as measured by FI was not significantly associated with increased hospital mortalityLe Maguet \[[@CR28]\]ICU mortality\
6-month mortalityMultivariate model: adjustment for sex, brain injury, cardiac arrest, SAPS II, GCS, memory disorders, severe sepsis, septic shock, dialysis, treatment with corticosteroids, BMI, and vasopressor useMortality:\
  ICU (FP \>2): HR 3.3, 1.6--6.6,*p* \< 0.001\
  ICU (CFS \>4): not significant\
  6 month (FP \>2): not significant\
  6 month (CFS \>4): HR 2.4, 1.5--3.9, *p* \< 0.001Yes: frailty values as measured by the FP and CFS were associated with increased ICU and 6-month mortality, respectively\
No: frailty values as measured by the CFS and FP were not associated with increased ICU and 6-month mortality, respectivelyMueller \[[@CR29]\]Adverse discharge disposition\
ICU LOS\
Hospital LOSMultivariate models: adjustment for age, APACHE II, co-morbidity, serum creatinine, hemoglobin level, GCSAdverse discharge disposition:\
  OR 8.01, 1.82--35.27, *p* = 0.006\
ICU LOS:\
  IRR 1.49, CI 1.17--1.89, *p* = 0.001\
Hospital LOS:\
  IRR 1.57, 1.35--1.82, *p* \< 0.001Yes: frailty as measured by an FI \> 0.25 was associated with increased risk of adverse discharge disposition and increased ICU/hospital LOSZeng \[[@CR34]\]30-day mortality\
300-day mortalityMultivariate models: age, sex, GCS, KS, PPS, APACHE II, APACHE IV, APSMortality:\
  30-day: for every 0.01 increase in FI: RRR 1.11, 1.07--1.15\
  300-day: for every 0.01 increase in FI: RRR 1.07, 1.04--1.11Yes: increasing frailty as measured by the FI was associated with increased risk of 30-day and 300-day mortality*HR* hazard ratio, *APACHE* acute physiology chronic health evaluation, *SOFA* sequential organ failure assessment, *IADL* instrumental activities of daily living, *BADL* basic activities of daily living, *RBANS* repeatable battery for the assessment of neuropsychological status, *SF*-*36* medical outcomes survey short form-36, *ADL* activities of daily living,*IQCODE* informant questionnaire on cognitive decline in the elderly,*CAM-ICU* confusion assessment method for the intensive care unit,*RASS* richmond agitation sedation scale, *MV* mechanical ventilation, *ICU* intensive care unit, *FI* frailty index, *OR* odds ratio, *CFS* clinical frailty score, *FP* frailty phenotype, *LOS* length of stay, *GCS* Glasgow coma scale, *KS* Karnofsky scale, *PPS* palliative performance scale, *APS* acute physiology score, *SAPS II*score simplified acute physiologic score II, *IRR* incidence rate ratio, *RRR* relative risk ratio^a^All ranges are 95% CI

Publication bias {#Sec23}
----------------

Publication bias was assessed visually using a funnel plot for hospital mortality; there was no significant evidence of publication bias (Appendix Fig. 9).

Discussion {#Sec24}
==========

Key findings {#Sec25}
------------

In this systematic review of 10 observational studies we found that frailty was common, occurring in approximately 30% of adult ICU admissions. We also found that frailty was associated with increased risk of hospital and long-term mortality and that frail patients were less likely to have home as a discharge destination. We found no significant difference among frail and non-frail patients in the receipt of mechanical ventilation, receipt of vasoactive therapy, or duration of ICU stay. Increasing severity of frailty was associated with worsened outcomes including hospital and long-term mortality and our findings were robust when we analyzed high quality studies, adjusted data, and in trial sequential analysis.

Context {#Sec26}
-------

Although frailty has been long recognized by geriatric medicine, it has only been recently identified as an important determinant of prognosis for critically ill patients and our systematic review supports this. Our findings are consistent with the observation that frail patients are at increased risk of poor outcomes in other settings and after healthcare interventions \[[@CR41], [@CR42]\]. Potential causes for poor outcomes experienced by critically ill frail patients include its underlying pathophysiology of neuromuscular weakness, sarcopenia, decreased oxygen utilization, inflammation, and immunosenescence \[[@CR9], [@CR18], [@CR43]\] reflecting a wide range of age-related molecular and cellular deficits \[[@CR44], [@CR45]\]. These may increase susceptibility to inflammatory insults and nosocomial infections common in critical illness. Diminished reserve arising from the multisystem nature of frailty may increase adverse effects of critical illness treatments such as bed rest, sedation, polypharmacy, instrumentation, and MV. Additionally, the reduced resilience of frail patients and increased likelihood of comorbid conditions \[[@CR46]\] may make their recovery more difficult \[[@CR47]\] and prolonged with reduced probability of returning to baseline increasing the chances of institutionalization \[[@CR5], [@CR6], [@CR18]\]. In our study, we found that frail ICU patients were at an increased risk of not being discharged home, although this was reported in only four studies.

We did not find significant differences in ICU LOS, although there was a non-statistically significant increase in hospital stay. The only study reporting duration of MV found no difference between frail and non-frail patients \[[@CR28]\]. This is unexpected since there are many factors, including diminished resilience, that may increase recovery time in frail patients prolonging their ICU and hospital stays as compared to non-frail patients. For example, frail patients may be more difficult to wean from mechanical ventilation because of weakness, sarcopenia, and decreased oxygen uptake \[[@CR9], [@CR17], [@CR18], [@CR43]\]. Further, as a result of immunosenescence, frail patients may need more time to recover from infections including those nosocomially acquired \[[@CR45]\]. Our results are not in keeping with data in surgical populations, which have demonstrated that frail patients have longer stays in hospital and recovery time \[[@CR6]\]. Possible reasons for these results include incomplete reporting of data, impact of end-of-life care or limitations of care influenced by frailty status, and discharge practices. A further factor that may have influenced the LOS data and duration of organ support is survival bias. Frail patients may have died earlier than the non-frail and this may have been associated with reduced LOS, as well as the duration of organ support. Data which would have allowed examination of this, such as "days alive and free of organ support", was rarely reported with only Bagshaw et al. finding that hospital LOS was prolonged in frail survivors. These data should be described in futures studies focused on frailty in ICU settings.

Implications for clinicians, policy, and research {#Sec27}
-------------------------------------------------

An important aspect of this work is to determine if ICU processes of care can be modified to improve outcomes for those identified as frail. Examples of processes which may have differential impact in those who are frail include nutritional support, sedation practices, intensity of mobilization/rehabilitation etc. While research is being conducted on how to improve outcomes, ongoing awareness of frailty as a marker of risk is important and may lead to better advanced care planning. Implicit in this is the recognition that frailty is not only associated with the elderly but may even occur in younger ages \[[@CR26], [@CR32]\]. Moreover, frailty may provide a better method to evaluate the trajectory of chronic health and its determinants such as cognition, mobility, function, and social engagement leading to ICU admission. Currents methods such as co-morbidity indices and chronic health evaluations integrated into illness severity scores and mortality prediction models are likely insufficient given the incremental impact of frailty on outcomes after adjusting for illness. Our work supports the value for implementation of frailty screening at the time of ICU admission. Since all the scales used in the included studies correlated with worsened outcomes; after further validation, the CFS which is the most studied, least time intensive, and easy to apply would be the most promising candidate.

ICU researchers and clinicians, who routinely measure co-morbidities, may question why frailty should be additionally measured or measured instead. The value of frailty is that it is a reflection of overall function which is not the case for co-morbidity, although frailty and co-morbidities are inherently intertwined in relation to the degree of frailty \[[@CR48]\]. Fried and colleagues attempted to "untangle" these constructs but there is considerable overlap which increases with age \[[@CR11]\]. Work on defining health deficit accumulation through network modeling shows that what matters the most is the density of a deficits connections to other deficits which is not captured by simple counting of deficits \[[@CR49]--[@CR51]\]. As an individual ages and accumulates deficits, as would be the case in many older people who are critically ill, the more that frailty and co-morbidity are inextricably intertwined.

Limitations {#Sec28}
-----------

Although the association between frailty and poor outcomes from critical illness is supported by its underlying pathophysiology, it should be emphasized that the studies in our review were observational, may have been prone to bias, and causation cannot be determined. Two key potential biases are selection and confirmation biases. None of the studies applied the gold standard for frailty determination which is a comprehensive geriatric assessment performed by a specialist in geriatric medicine \[[@CR52]\]. All these studies identified patients after ICU admission and we have no data on frail and non-frail patients declined ICU admission. In addition, the perception and identification of frailty may have influenced care received and limitations of care. Similarly we are unable to ascertain the role of survival bias in our results. Furthermore, we were limited in our ability to pool adjusted data because of heterogeneity in its reporting. However, supporting the importance of frailty as a determinant of outcome was that high quality studies which controlled for age and other co-founders including illness severity found that frailty was independently associated with adverse outcomes. In addition, we found that frail and non-frail patients had similar rates of mechanical ventilation and use of vasopressors reducing the likelihood of care limitations. Moreover, in most of the studies there was a frailty dose response where increasing frailty correlated with increasingly worse outcomes.

An additional limitation is that the included studies used three different frailty measures: the CFS, FP, and FI. We included all of these studies since frailty measures generally correlate well with each other \[[@CR13]\]. When we performed subgroup analysis the results remained similar across all measures of frailty. However, unanswered questions remain including which is the most appropriate measure in the ICU setting? Should there be an ICU-specific frailty measure? Does it matter which measure if they all show similar trends for outcome? If this is the case, the one that is least time consuming and most feasible may be a reasonable starting point. Limitations also include variable reporting of outcomes, data originating from different healthcare settings, and need to transform data for aggregation. Further, the late registry in PROSPERO, the addition of long-term mortality as an outcome, and lack of a published protocol with a statistical plan could all increase the risk of bias.

Conclusions {#Sec29}
===========

Clinically frail patients are at increased risk of adverse outcomes because of physiological vulnerability when stressors are experienced. In this study, we demonstrate significantly increased risk of mortality and adverse outcomes in critically ill frail patients. Routine assessment of frailty at ICU admission may provide clinicians prognostic information for survival and recovery for their frail ICU patients. Importantly, this may help patients and their families make informed decisions about goals-of-care when they are critically ill. Importantly, further research is required to determine if there are modifiable factors that can improve outcomes for critically ill frail patients.

Electronic supplementary material
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**Take-home message:**Frailty is an important baseline characteristic of patients who are critically ill. In this meta-analysis, we show that critically ill frail patients, compared to non-frail patients, are at increased risk of mortality, adverse outcomes, and are less likely to be discharged home.

**Electronic supplementary material**

The online version of this article (doi:10.1007/s00134-017-4867-0) contains supplementary material, which is available to authorized users.

We would like to acknowledge and are grateful to Dr. Nathan Brummel and Dr. Aluko Hope for providing additional data from their studies. We would also like to acknowledge the Canadian Frailty Network for facilitating this work.

JM conceived and supervised the study, extracted data, performed data analysis, and developed the manuscript. BW extracted data, performed data analysis, and developed the manuscript. AV extracted data, performed data analysis, and provided input on manuscript development. SMB, JGB, DM, SS, and KR provided input on data interpretation, helped write the manuscript, and provided critical input on its revisions.

Conflicts of interest {#FPar1}
=====================

Braden Waters, Aditya Varambally, Sean M Bagshaw, Stephanie Sibley, and David Maslove declare that no conflicts of interest exist. J. Gordon Boyd: Dr. Boyd receives a stipend from the Trillium Gift of Life Network to support his role as the Hospital Donation Physician. Kenneth Rockwood: President and Chief Scientific Officer of DGI Clinical, which has contracts with pharma on individualized outcome measurement. In July 2015 he gave a lecture at the Alzheimer Association International Conference in a symposium sponsored by Otsuka and Lundbeck. At that time he presented at an Advisory Board meeting for Nutricia. He plans to attend a 2017 advisory board meeting for Lundbeck. He is a member of the Research Executive Committee of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian Institutes of Health Research, with additional funding from the Alzheimer Society of Canada and several other charities, as well as from Pfizer Canada and Sanofi Canada. He receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, and research support from the Nova Scotia Health Research Foundation, the Capital Health Research Fund, and the Fountain Family Innovation Fund of the Nova Scotia Health Authority Foundation. John Muscedere. Dr. Muscedere is the Scientific Director for the Canadian Frailty Network which is funded by the government of Canada.
